TU Darmstadt / ULB / TUbiblio

Treatment and management of primary antibody deficiency: German interdisciplinary evidence‐based consensus guideline

Hanitsch, Leif ; Baumann, Ulrich ; Boztug, Kaan ; Burkhard‐Meier, Ulrike ; Fasshauer, Maria ; Habermehl, Pirmin ; Hauck, Fabian ; Klock, Gerd ; Liese, Johannes ; Meyer, Oliver ; Müller, Rainer ; Pachlopnik‐Schmid, Jana ; Pfeiffer‐Kascha, Dorothea ; Warnatz, Klaus ; Wehr, Claudia ; Wittke, Kirsten ; Niehues, Tim ; Bernuth, Horst von (2024)
Treatment and management of primary antibody deficiency: German interdisciplinary evidence‐based consensus guideline.
In: European Journal of Immunology : Basic, Clinical, Translational, 2020, 50 (10)
doi: 10.26083/tuprints-00017813
Artikel, Zweitveröffentlichung, Verlagsversion

WarnungEs ist eine neuere Version dieses Eintrags verfügbar.

Kurzbeschreibung (Abstract)

This evidence‐based clinical guideline provides consensus‐recommendations for the treatment and care of patients with primary antibody deficiencies (PADs). The guideline group comprised 20 clinical and scientific expert associations of the German, Swiss, and Austrian healthcare system and representatives of patients. Recommendations were based on results of a systematic literature search, data extraction, and evaluation of methodology and study quality in combination with the clinical expertise of the respective representatives. Consensus‐based recommendations were determined via nominal group technique. PADs are the largest clinically relevant group of primary immunodeficiencies. Most patients with PADs present with increased susceptibility to infections, however immune dysregulation, autoimmunity, and cancer affect a significant number of patients and may precede infections. This guideline therefore covers interdisciplinary clinical and therapeutic aspects of infectious (e.g., antibiotic prophylaxis, management of bronchiectasis) and non‐infectious manifestations (e.g., management of granulomatous disease, immune cytopenia). PADs are grouped into disease entities with definitive, probable, possible, or unlikely benefit of IgG‐replacement therapy. Summary and consensus‐recommendations are provided for treatment indication, dosing, routes of administration, and adverse events of IgG‐replacement therapy. Special aspects of concomitant impaired T‐cell function are highlighted as well as clinical data on selected monogenetic inborn errors of immunity formerly classified into PADs (APDS, CTLA‐4‐, and LRBA‐deficiency).

Typ des Eintrags: Artikel
Erschienen: 2024
Autor(en): Hanitsch, Leif ; Baumann, Ulrich ; Boztug, Kaan ; Burkhard‐Meier, Ulrike ; Fasshauer, Maria ; Habermehl, Pirmin ; Hauck, Fabian ; Klock, Gerd ; Liese, Johannes ; Meyer, Oliver ; Müller, Rainer ; Pachlopnik‐Schmid, Jana ; Pfeiffer‐Kascha, Dorothea ; Warnatz, Klaus ; Wehr, Claudia ; Wittke, Kirsten ; Niehues, Tim ; Bernuth, Horst von
Art des Eintrags: Zweitveröffentlichung
Titel: Treatment and management of primary antibody deficiency: German interdisciplinary evidence‐based consensus guideline
Sprache: Englisch
Publikationsjahr: 12 Februar 2024
Ort: Darmstadt
Publikationsdatum der Erstveröffentlichung: 2020
Ort der Erstveröffentlichung: Weinheim
Verlag: Wiley-VCH
Titel der Zeitschrift, Zeitung oder Schriftenreihe: European Journal of Immunology : Basic, Clinical, Translational
Jahrgang/Volume einer Zeitschrift: 50
(Heft-)Nummer: 10
DOI: 10.26083/tuprints-00017813
URL / URN: https://tuprints.ulb.tu-darmstadt.de/17813
Zugehörige Links:
Herkunft: Zweitveröffentlichung DeepGreen
Kurzbeschreibung (Abstract):

This evidence‐based clinical guideline provides consensus‐recommendations for the treatment and care of patients with primary antibody deficiencies (PADs). The guideline group comprised 20 clinical and scientific expert associations of the German, Swiss, and Austrian healthcare system and representatives of patients. Recommendations were based on results of a systematic literature search, data extraction, and evaluation of methodology and study quality in combination with the clinical expertise of the respective representatives. Consensus‐based recommendations were determined via nominal group technique. PADs are the largest clinically relevant group of primary immunodeficiencies. Most patients with PADs present with increased susceptibility to infections, however immune dysregulation, autoimmunity, and cancer affect a significant number of patients and may precede infections. This guideline therefore covers interdisciplinary clinical and therapeutic aspects of infectious (e.g., antibiotic prophylaxis, management of bronchiectasis) and non‐infectious manifestations (e.g., management of granulomatous disease, immune cytopenia). PADs are grouped into disease entities with definitive, probable, possible, or unlikely benefit of IgG‐replacement therapy. Summary and consensus‐recommendations are provided for treatment indication, dosing, routes of administration, and adverse events of IgG‐replacement therapy. Special aspects of concomitant impaired T‐cell function are highlighted as well as clinical data on selected monogenetic inborn errors of immunity formerly classified into PADs (APDS, CTLA‐4‐, and LRBA‐deficiency).

Freie Schlagworte: autoimmunity, CVID, hypogammaglobulinemia, immunoglobulins, primary antibody deficiency
Status: Verlagsversion
URN: urn:nbn:de:tuda-tuprints-178138
Sachgruppe der Dewey Dezimalklassifikatin (DDC): 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin, Gesundheit
Fachbereich(e)/-gebiet(e): 07 Fachbereich Chemie
07 Fachbereich Chemie > Clemens-Schöpf-Institut
Hinterlegungsdatum: 12 Feb 2024 13:57
Letzte Änderung: 13 Feb 2024 07:45
PPN:
Zugehörige Links:
Export:
Suche nach Titel in: TUfind oder in Google

Verfügbare Versionen dieses Eintrags

Frage zum Eintrag Frage zum Eintrag

Optionen (nur für Redakteure)
Redaktionelle Details anzeigen Redaktionelle Details anzeigen